Liraglutide
FDA ApprovedAlso known as: Victoza, Saxenda
GLP-1 AgonistLast reviewed: April 28, 2026
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and tirzepatide. While largely superseded by newer agents for weight loss, it remains FDA-approved and widely prescribed, particularly for patients who tolerate it well or have established insurance coverage.
Mechanism of Action
Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Requires daily injection due to a shorter half-life than semaglutide. The daily dosing schedule is both a limitation and, for some patients, a feature — easier to stop quickly if side effects occur.
Common Uses
- Weight management (FDA-approved as Saxenda)
- Type 2 diabetes (FDA-approved as Victoza)
- Cardiovascular risk reduction
Known Risks
- Nausea and vomiting (common, especially during titration)
- Pancreatitis risk
- Gallbladder disease
- Potential thyroid C-cell tumor risk (animal data)
- Daily injection burden vs. weekly alternatives
Regulatory Status
FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). The LEADER trial demonstrated cardiovascular risk reduction in diabetic patients. Largely superseded by semaglutide and tirzepatide for new prescriptions due to superior efficacy and weekly dosing, but remains a valid option with established long-term safety data.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection (Saxenda/Victoza)
Typical Dose
0.6 mg → 3.0 mg (titrated over 5 weeks)
Frequency
Once daily
Cycle Length
Ongoing — not typically cycled
Titrate slowly: 0.6 mg week 1, 1.2 mg week 2, 1.8 mg week 3, 2.4 mg week 4, 3.0 mg week 5. Daily injection is the main practical disadvantage vs. weekly semaglutide. Inject in abdomen, thigh, or upper arm.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.